Prevalence of Helicobacter Pylori on Patients With Chronic Inflammatory Bowel Disease (IBD) at the CHU of Guadeloupe
Overview
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Prevalence of H. pylori infection in patients with Inflammatory Bowel Disease (IBD)
Overview
Brief Summary
Clinical and experimental data suggest that dysbiosis may play a pivotal role in the pathogenesis of intestinal bowel disease (IBD). However, to the best of our knowledge, the composition of gastric and of intestinal microbiome has never been investigated in a population with IBD according to the presence/absence of Helicobacter pylori (H. pylori) in the stomach.
Detailed Description
H. pylori infection is one of the most widely spread infectious diseases in humans. Although the pathogenesis of IBD is unknown, this pathology could result from complex interactions between environmental factors and the intestinal microbiota, with dysbiosis likely being a key factor. In theory, H. pylori infection could be involved in the pathogenesis of IBD by inducing alterations in gastric and/or intestinal permeability or by causing immunological derangements. However, various studies indicate that the prevalence of H. pylori infection is low in patients with IBD, suggesting a protective role for this infection in the development of IBD.
The objective of the study is to investigate the potential link between H. pylori infection and IBD. Another objective is to analyze the complex interactions between the gastric and intestinal microbiome in a population with IBD according to the presence or absence of H. pylori in the stomach.
The study will be based on a prospective cohort of patients with IBD receiving medical care at the CHU of Guadeloupe.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients over 18 years old Patients with IBD from the CHU of Guadeloupe Patients benefiting from an investigation of H. pylori infection through gastric biopsies and/or serology at the time of diagnosis of IBD Patients affiliated to the French social security system Free informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research)
Exclusion Criteria
- •Patients of less than18 years Patients having not given their writing informed consent
Outcomes
Primary Outcomes
Prevalence of H. pylori infection in patients with Inflammatory Bowel Disease (IBD)
Time Frame: At the time of endoscopic evaluation (baseline only).
Presence of Helicobacter pylori infection determined using gastric biopsies collected during clinically indicated upper gastrointestinal endoscopy. Infection status will be confirmed by standard histological assessment performed as part of routine care. The prevalence will be expressed as the proportion of IBD patients with confirmed H. pylori infection among all included IBD patients in the cohort.
Secondary Outcomes
- Demographic characteristics according to H. pylori infection status(Baseline.)
- Clinical characteristics according to H. pylori infection status(Baseline.)
- Biological inflammatory markers according to H. pylori infection status(Baseline.)
- IBD-related treatments according to H. pylori infection status(Baseline.)
- Prevalence of gastric intestinal metaplasia and dysplasia according to H. pylori infection status(Baseline.)
- Composition of the gastric microbiome according to H. pylori infection status(Baseline.)